A randomized trial comparing terlipressin and noradrenaline in patients with cirrhosis and septic shock

Liver International

Volumn 37, Issue 4, 2017, Pages 552-561

  Choudhury, Ashok ^a   Kedarisetty, Chandan K ^a   Vashishtha, Chitranshu ^a   Saini, Deepak ^a   Kumar, Sachin ^a   Maiwall, Rakhi ^a   Sharma, Manoj K ^a   Bhadoria, Ajeet S ^a   Kumar, Guresh ^a   Joshi, Yogendra K ^a   Sarin, Shiv K ^a  

^a INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

cirrhosis; septic shock; terlipressin; vasopressor

Indexed keywords

LACTIC ACID; NORADRENALIN; TERLIPRESSIN; LYPRESSIN; VASOCONSTRICTOR AGENT;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BACTERIAL PERITONITIS; BRADYCARDIA; CONTROLLED STUDY; CYANOSIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMIC PARAMETERS; HOSPITALIZATION; HUMAN; HYPOTENSION; INCIDENCE; LACTIC ACIDOSIS; LIVER CIRRHOSIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; MIDDLE AGED; MONOTHERAPY; MORTALITY; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL CYANOSIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SEPTIC SHOCK; SURVIVAL PREDICTION; TISSUE PERFUSION; ANALOGS AND DERIVATIVES; BLOOD; COMPLICATION; HEMODYNAMICS; INDIA; KAPLAN MEIER METHOD; STATISTICAL MODEL;

ADULT; FEMALE; HEMODYNAMICS; HUMANS; INDIA; KAPLAN-MEIER ESTIMATE; LACTIC ACID; LIVER CIRRHOSIS; LOGISTIC MODELS; LYPRESSIN; MALE; MICROCIRCULATION; MIDDLE AGED; NOREPINEPHRINE; SHOCK, SEPTIC; VASOCONSTRICTOR AGENTS;

EID: 84995938572     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13252     Document Type: Article

References (30)

1. Russell James A. Management of sepsis. N Engl J Med. 2006;355:1699–1713.
2. Arvaniti V, D'Amico G, Fede G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139:1246–1256.
3. Gustot T, Francois D, Lebrec D, et al. Severe sepsis in cirrhosis. Hepatology. 2009;50:2022–2033.
4. Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. Dec 2010;16:347–352.
5. Kimmoun A, Ducrocq N, Levy B. Mechanisms of vascular hyporesponsiveness in septic shock. Curr Vasc Pharmacol. 2013;2:139–149.
6. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation. 1997 Mar 4;95:1122–1125.
7. Neto AS, Nassar AP Jr, Cardoso SO, et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012;16:R154.
8. Morelli A, Ertmer C, Rehberg S, et al. Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study. Crit Care. 2009;13:R130–R143.
9. Krag A, Borup T, Møller S, et al. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenalsyndrome. Adv Ther. 2008;25:1105–1140.
10. James R, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–887.
11. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864–874.
12. Phillip D, Mitchell LM, Andrew R, et al. Surviving Sepsis Campaign: international Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med. 2013;41:580–637.
13. Jones AE, Shapiro NI, Trzeciak S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA. 2010;8:739–746.
14. Shin TG, Jo IJ, Hwang SY, et al. Comprehensive interpretation of central venous oxygen saturation and blood lactate levels during resuscitation of patients with severe sepsis and septic shock in the emergency department. Shock. 2016;45:4–9.
15. Lange M, Bröking K, Ertmer C, et al. Rebound hypotension following terlipressin bolus infusion can be prevented by continuous low-dose infusion of terlipressin. Crit Care. 2007;11(Suppl. 2):P35.
16. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov. Accessed March 31, 2003. Publish Date: August 9, 2006.
17. Rinaldi L, Ferrari E, Marietta M, et al. Effectiveness of sepsis bundle application in cirrhotic patients with septic shock: a single-center experience. J Crit Care. 2013;28:152–157.
18. Jalan R, Hayes PC. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure. Gut. 2000;46:527–533.
19. Henriksen JH, Kiszka-Kanowitz M, Bendtsen F. Volume expansion in patients with cirrhosis. Aliment Pharmacol Ther. 2002;16(Suppl. 5):12–23.
20. Leibovici L, Gafter-gvili A, Paul M, et al. Relative tachycardia in patients with sepsis: an independent risk factor for mortality. Q J Med. 2007;100:629–634.
21. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med. 1997;25:1279–1282.
22. Galbois A, Bigé N, Pichereau C, et al. Exploration of skin perfusion in cirrhotic patients with septic shock. J Hepatol. 2015 Mar;62:549–555.
23. De Backer D, Donadello K, Sakr Y, et al. Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med. 2013;41:791–799.
24. Poeze M, Solberg BC, Greve JW, et al. Monitoring global volume-related hemodynamic or regional variables after initial resuscitation: what is a better predictor of outcome in critically ill septic patients? Crit Care Med. 2005;33:2494–2500.
25. Xiao X, Zhang J, Wang Y, et al. Effects of terlipressin on patients with sepsis via improving tissue blood flow. J Surg Res. 2016 Jan;200:274–282.
26. Rodríguez E, Elsa CE, Barreto SR, et al. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. J Hepatol. 2014 May;60:955–961.
27. Benavides J, Fernandez N, Colombato L, et al. Further evidence linking bacterial infection and upper G.I. bleeding in cirrhosis. Results from a large multicentric prospective survey in Argentina. J Hepatol. 2003;38(Suppl. 2):A176.
28. Choudhury AK, Kedarisetty CK, Wagle P, et al. Predictors of terlipressin related adverse effects in liver cirrhosis and its influence on survival. J Hepatol. 2014;60:S16
29. Acevedo JG, Fernandez J, Escorsell A, Mas A, Gines P, Arroyo V. Clinical efficacy and safety of Terlipressin administration in cirrhotic patients with septicshock. J Hepatol. 2009;50:S-1:P–S73.
30. Cavallin M, Piano S, Angeli P, et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: a randomized controlled study. Hepatology. 2016;63:983–992.